You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

Claims for Patent: 6,683,230


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,683,230
Title: Hybrid seed production
Abstract:Methods of preparing hybrid seed are described. One such method comprises interplanting a male parent plant which is male fertile and homozygous recessive female sterile and a female parent plant which is homozygous recessive male sterile and female fertile, allowing cross-pollination and obtaining the seed produced therefrom. The genomic material of each parent plant may also have integrated therein a gene construct comprising a promoter sequence-responsive to the presence or absence of an exogenous chemical inducer, optionally operably linked to one or more enhancer or intron sequences, operably linked to a gene which fully restores the fertility of each parent plant, the gene being expressed by the application to the plant of an external chemical inducer thereby allowing each parent to self-pollinate.
Inventor(s): Jepson; Ian (Bracknell, GB), Daly; Allan (Bracknell, GB), Knight; Mary Elizabeth (Eaton, GB), Bayliss; Michael William (Haslemere, GB)
Assignee: Syngenta Limited (GB)
Application Number:09/601,812
Patent Claims:1. A method of producing hybrid seed comprising incorporating a first expression cassette into a first plant to generate a hemizygous female parent plant, said first expression cassette comprising: (a) a first gene promoter sequence which is a male flower specific promoter; (b) a disrupter gene encoding a protein capable of disrupting male fertility operably linked to the first gene promoter sequence; (c) a second gene promoter sequence which is a female tissue specific promoter sequence optionally operably linked to one or more translational enhancer or intron sequences; (d) a restorer gene encoding a protein capable of restoring female fertility operably linked to the second gene promoter sequence; (e) a third gene promoter sequence responsive to the presence or absence of an exogenous chemical inducer said third gene promoter sequence optionally operably linked to one or more translational enhancer or intron sequences; and (f) a restorer gene encoding a protein capable of restoring male fertility operably linked to the third gene promoter sequence;

whereby the presence of the exogenous chemical inducer controls male fertility; and incorporating a second expression cassette into a second plant to generate a hemizygous male parent plant, said second expression cassette comprising: (g) a first gene promoter sequence which is a female flower specific promoter sequence; (h) a disrupter gene encoding a protein capable of disrupting female fertility; (i) a second gene promoter sequence which is a male tissue specific promoter sequence optionally operably linked to one or more enhancer or intron sequences; (j) a restorer gene encoding a protein capable of restoring male fertility operably linked to the second gene promoter sequence; (k) a third gene promoter sequence responsive to the presence or absence of an exogenous chemical inducer, said third gene promoter sequence optionally operably linked to one or more enhancer or intron sequences; and (l) a restorer gene encoding a protein capable of restoring female fertility operably linked to the third gene promoter sequence; whereby the presence of the exogenous chemical inducer controls female fertility; applying an exogenous chemical inducer to the transformants thereby allowing the plants to self-pollinate; growing up plants from the resulting seed; selecting for male and female homozygous plants; crossing the selected male and female plants; and obtaining the resulting hybrid seed.

2. A method according to claim 1 wherein the male flower specific promoter sequence is a gametophytic promoter sequence.

3. A method according to claim 1 wherein the male flower specific promoter sequence is a sporophytic promoter sequence.

4. A method according to claim 1 wherein the plants are selected from the group consisting of wheat, rice, maize, tomato, sunflower, sugarbeet, canola, cotton, soybean and other vegetables.

5. A method according to claim 1 wherein the disrupter gene encoding a product capable of disrupting male fertility encodes a product which is capable of disrupting pollen production.

6. A method according to claim 1 wherein the third gene promoter sequece is the AlcA promoter sequence or the GST-27 promoter sequence.

7. A method according to claim 1 wherein the restorer gene encoding a product capable of restoring male fertility encodes a product which is capable of restoring pollen producting.

8. Hybrid seed resulting from the method of claim 1, which hybrid seed comprises the first and second expression cassettes according to claim 1.

Details for Patent 6,683,230

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2018-02-20
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2018-02-20
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2018-02-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.